Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company known for its innovative treatments in areas like HIV, liver diseases, and oncology. On February 11, 2026, BMO Capital maintained its "Outperform" rating for GILD, with the stock priced at $147.23. BMO Capital also raised Gilead's price target from $150 to $160, reflecting confidence in the company's future performance.
Gilead's Q4 2025 earnings call highlighted strong financial results, with total product sales reaching $7.9 billion, a 5% increase from the previous year. For the full year 2025, sales were $28.9 billion, up 1% from 2024. The company's HIV sales were particularly strong, with a 6% year-over-year increase, driven by the success of Biktarvy and a 47% growth in the HIV prevention portfolio.
Gilead's new HIV prevention injectable, Yeztugo, has exceeded coverage goals and is gaining market share. The company also has a robust pipeline, with up to 10 ongoing and potential new launches through 2027, including four commercial launches planned for 2026. This pipeline is expected to support Gilead's growth in the coming years.
In addition to its HIV business, Gilead reported a 6% growth in its Liver business, thanks to the adoption of Livdelzi for primary biliary cholangitis. Trodelvy, an oncology product, also showed positive momentum with a 6% growth in 2025, supported by positive Phase results. These developments highlight Gilead's diversified portfolio and potential for future growth.
The current stock price of $147.23 reflects a decrease of 2.93%, with a change of $4.45. The stock has fluctuated between a low of $147.07 and a high of $151.87 today, with a market capitalization of approximately $182.67 billion and a trading volume of 10.72 million shares.
